Literature DB >> 20021343

The insulin-like growth factor-1 axis and its potential as a therapeutic target in central nervous system (CNS) disorders.

Olivia Bibollet-Bahena1, Qiao-Ling Cui, Guillermina Almazan.   

Abstract

The insulin-like growth factor-1 (IGF-1) is a pleiotropic factor. Many studies have revealed its importance in the development and maintenance of the central nervous system (CNS). This review will discuss the IGF-1 axis, from the factor itself to the signalling pathways it activates, and its tight regulation. Particular focus will be brought on potential therapeutic targets of the IGF-1 axis in CNS disorders, including brain tumours and neurodegenerative diseases affecting neurons and oligodendrocytes.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20021343     DOI： 10.2174/187152409788452108

Source DB:  PubMed          Journal:  Cent Nerv Syst Agents Med Chem        ISSN： 1871-5249


  8 in total

1.  The relationships between IGF-1 and CRP, NO, leptin, and adiponectin during weight loss in the morbidly obese.

Authors:  Eva Pardina; Roser Ferrer; Juan Antonio Baena-Fustegueras; Albert Lecube; Jose Manuel Fort; Víctor Vargas; Roberto Catalán; Julia Peinado-Onsurbe
Journal:  Obes Surg       Date:  2010-05       Impact factor: 4.129

Review 2.  Targeting Insulin-Like Growth Factor-I in Management of Neurological Disorders.

Authors:  Rashita Makkar; Tapan Behl; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Hafiz A Makeen; Mohammed Albratty; Hassan A Alhazmi; Aldulkarim M Meraya
Journal:  Neurotox Res       Date:  2022-04-27       Impact factor: 3.911

3.  Circulating Insulin-Like Growth Factor 1 Levels and Migraine Risk: A Mendelian Randomization Study.

Authors:  Reziya Abuduxukuer; Peng-Peng Niu; Zhen-Ni Guo; Yu-Ming Xu; Yi Yang
Journal:  Neurol Ther       Date:  2022-09-01

4.  The antiaging protein Klotho enhances oligodendrocyte maturation and myelination of the CNS.

Authors:  Ci-Di Chen; Jacob A Sloane; Hu Li; Nurgul Aytan; Eustathia L Giannaris; Ella Zeldich; Jason D Hinman; Alpaslan Dedeoglu; Douglas L Rosene; Rashmi Bansal; Jennifer I Luebke; Makoto Kuro-o; Carmela R Abraham
Journal:  J Neurosci       Date:  2013-01-30       Impact factor: 6.167

5.  Central administration of insulin-like growth factor-I decreases depressive-like behavior and brain cytokine expression in mice.

Authors:  Sook-Eun Park; Robert Dantzer; Keith W Kelley; Robert H McCusker
Journal:  J Neuroinflammation       Date:  2011-02-09       Impact factor: 8.322

6.  Insulin-like growth factor-I peptides act centrally to decrease depression-like behavior of mice treated intraperitoneally with lipopolysaccharide.

Authors:  Sook-Eun Park; Marcus Lawson; Robert Dantzer; Keith W Kelley; Robert H McCusker
Journal:  J Neuroinflammation       Date:  2011-12-21       Impact factor: 8.322

7.  Nogo receptor inhibition enhances functional recovery following lysolecithin-induced demyelination in mouse optic chiasm.

Authors:  Fereshteh Pourabdolhossein; Sabah Mozafari; Ghislaine Morvan-Dubois; Javad Mirnajafi-Zadeh; Alejandra Lopez-Juarez; Jacqueline Pierre-Simons; Barbara A Demeneix; Mohammad Javan
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

8.  Neuroprotective effects of enriched environment housing after transient global cerebral ischaemia are associated with the upregulation of insulin-like growth factor-1 signalling.

Authors:  Magdalena Wadowska; Julie Woods; Magdalena Rogozinska; Teresita L Briones
Journal:  Neuropathol Appl Neurobiol       Date:  2015-04-23       Impact factor: 8.090
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.